Tadeg Hailu, Berhane Yemane
Management Sciences for Health (MSH), Addis Ababa, Ethiopia.
East Afr J Public Health. 2012 Jun;9(2):85-9.
The objective of this review is to produce evidence on the prevalence and trends in the availability of substandard and counterfeit antimicrobials in the global market and its consequences on key public health interventions in developing countries
Review of various literatures collected through the internet and other sources. Literature search using PubMed and Medline databases and Google search engine was conducted to identify related publications on the subject. Relevant published and unpublished literature was also consulted as additional source of information.
During the past few decades, the trade of substandard and counterfeit medicines has increased substantially. Past experiences indicate that almost any kind of medicine can be counterfeited. In developing countries, primary targets are those antimicrobials that are commonly used in the treatment of life-threatening conditions including malaria, tuberculosis and HIV/AIDS. The findings in this review support the strong contention that substandard and counterfeit antimicrobials are available in the developing world in very high proportions. This is becoming one of the major causes of treatment failures leading to excessive mortality and morbidity. Moreover, it is implicated for contributing to the development of drug resistant organisms in many infectious diseases of public health significance such as malaria, tuberculosis and HIV/AIDS.
If trends in the prevalence of counterfeit/substandard drugs continue at the current scale, there is a huge threat to interventions underway on major killer diseases in the developing world. So, public health interventions in developing countries should include quality control of antimicrobials as an integral part of program implementation. The national drug regulatory authorities in those countries should also be strengthened to enhance their capacity in enforcing regulations pertaining the registration, production, distribution and use of antimicrobial drugs.
本综述的目的是提供关于全球市场上不合格和假冒抗菌药物的可获得性及其对发展中国家关键公共卫生干预措施影响的患病率和趋势的证据。
回顾通过互联网和其他来源收集的各种文献。使用PubMed和Medline数据库以及谷歌搜索引擎进行文献检索,以识别关于该主题的相关出版物。还查阅了相关的已发表和未发表文献作为额外的信息来源。
在过去几十年中,不合格和假冒药品的贸易大幅增加。过去的经验表明,几乎任何一种药品都可能被假冒。在发展中国家,主要目标是那些常用于治疗包括疟疾、结核病和艾滋病毒/艾滋病等危及生命疾病的抗菌药物。本综述的结果支持了一个强烈的观点,即不合格和假冒抗菌药物在发展中世界的比例非常高。这正成为导致治疗失败、死亡率和发病率过高的主要原因之一。此外,它还被认为在许多具有公共卫生意义的传染病如疟疾、结核病和艾滋病毒/艾滋病中促进了耐药生物体的发展。
如果假冒/不合格药品的流行趋势继续以目前的规模发展,对发展中世界正在进行的主要致命疾病干预措施将构成巨大威胁。因此,发展中国家的公共卫生干预措施应将抗菌药物的质量控制作为项目实施的一个组成部分。这些国家的国家药品监管当局也应得到加强,以提高其执行有关抗菌药物注册、生产、分销和使用法规的能力。